“…Levels two and three represent those with mild or severe systemic disease. Of the studies assessed, eleven included patients with an ASA grade of I‐II (Bisgaard et al, ; Faria et al, ; Hausel et al, ; Hausel, Nygren, Thorell, Lagerkranser, & Ljungqvist, ; Kaška et al, ; Noblett et al, ; Pexe‐Machado, Oliveira, Dock‐Nascimento, & Aguilar‐Nascimento, ; Sada et al, ; Yagmurdur, Gunal, Yildiz, Gulec, & Topkaya, ; Yildiz, Gunal, Yilmaz, & Yucel, ; Yilmaz et al, ), five studies included patients with ASA grade of I‐III (Mathur et al, ; Pędziwiatr et al, ; Savluk et al, ; Wang, Wang, Wang, & Qin, ; Yang, Yan‐Bing, Xue‐Long, Dong, & Zhi‐Hao, ), and six trials did not state the patients’ ASA grade (Järvelä, Maaranen, & Sisto, ; Lidder et al, ; Rapp‐Kesek, Stridsberg, Andersson, Berne, & Karlsson, ; Singh et al, ; Webster et al, ; Yuill, Richardson, Davidson, Garden, & Parks, ).…”